A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.

Trial Profile

A multi-centre, randomized, double blind, placebo-controlled, parallel group study to investigate efficacy and safety of ONO-2506PO compared to placebo, in the presence of riluzole, to patients diagnosed with amyotrophic lateral sclerosis (ALS), who have had onset of muscle weakness within 14 months of randomization.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs Arundic acid (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
    • 11 Dec 2008 Actual trial completion date identified as December 2008 from ClinicalTrials.gov.
    • 11 Dec 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top